Loading…
Lithium nephropathy in Bipolar Disorder: a clinical challenge
IntroductionLithium nephropathy can occur in long-term lithium-treated bipolar disorder patients. Key risk factors include duration of lithium exposure, cumulative dose, acute intoxication episodes, advanced age, and comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyp...
Saved in:
Published in: | European psychiatry 2024-08, Vol.67 (S1), p.S429-S430 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | S430 |
container_issue | S1 |
container_start_page | S429 |
container_title | European psychiatry |
container_volume | 67 |
creator | Alario-Ruiz, C Arribas-Simon, B MartinezGimeno, P Calvo-Valcarcel, M Martin-Santiago, O |
description | IntroductionLithium nephropathy can occur in long-term lithium-treated bipolar disorder patients. Key risk factors include duration of lithium exposure, cumulative dose, acute intoxication episodes, advanced age, and comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia, along with concurrent use of antipsychotics. The clinical presentation is gradual, with mild proteinuria, often accompanied by arginine vasopressin resistance. Histological studies show a correlation between interstitial fibrosis and cumulative lithium duration. Approximately 15 to 25 per cent of exposed patients may experience a gradual decline in glomerular filtration rate. The outcome after lithium discontinuation varies.ObjectivesThis case study aims to analyze and document the clinical presentation, diagnosis, and management of lithium nephropathy in a patient with Bipolar Disorder.MethodsWe gathered data on the medical history, lab results, and treatment approach for a patient with Bipolar Disorder.ResultsThe patient, a 50-year-old woman, had been under the care of Psychiatry since 2008 due to a diagnosis of Bipolar Disorder Type I. During this time, she had experienced depressive and manic episodes but had not presented significant symptom decompensation for the past 14 years, successfully managed with lithium at a current dose of 600 mg per day. However, on this occasion, the patient sought hospitalization due to recent behavioural disturbances, including restlessness, disinhibition, abrupt changes in behaviour, pressured speech, sleep problems, agitation, and aggression. The patient also reported an increased sense of polyuria and polydipsia. Evaluation in the emergency department revealed elevated lithium levels of 1.47 mmol/L and hypokalemia, that justified lithium withdrawal. After lithium levels decreased, an estimated glomerular filtration rate remained low. She was diagnosed with lithium nephropathy, an adverse effect of long-term lithium therapy. Treatment with lithium changed to sodium valproate. Treatment with asenapine started and sustained for two months. Over the following two years, the patient experienced four additional hospital admissions in Psychiatry due to manic episodes.ConclusionsLong-term lithium therapy can lead to lithium nephropathy with symptoms such as polyuria, polydipsia, and acute kidney failure. Consistent monitoring of patients receiving lithium is crucial to detect potential adverse effects.This case highligh |
doi_str_mv | 10.1192/j.eurpsy.2024.890 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e36209fbfd11460ab3735fefda30e329</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e36209fbfd11460ab3735fefda30e329</doaj_id><sourcerecordid>3097364854</sourcerecordid><originalsourceid>FETCH-LOGICAL-d1370-89850687cb8f537188055b17339324a94390d19d60ddc8445dac40204bc0683e3</originalsourceid><addsrcrecordid>eNotzk9LwzAYBvAgCs7pB_BW8Nz5Jm_SJIIHnf8GAy96LmmSrildU9P2sG_vcJ4eeOD58RByS2FFqWb37crPaRgPKwaMr5SGM7KgUqochRLnZAGa8VwjqktyNY4tAJUAxYI8bsPUhHmf9X5oUhzM1Byy0GfPYYidSdlLGGNyPj1kJrNd6IM1XWYb03W-3_lrclGbbvQ3_7kk32-vX-uPfPv5vlk_bXNHUUKutBJQKGkrVQuUVCkQoqISUSPjRnPU4Kh2BThnFefCGcuBAa_scYYel2Rzcl00bTmksDfpUEYTyr8ipl1p0hRs50uPBQNdV7WjlBdgKpQoal87g-CR6aN1d7KGFH9mP05lG-fUH--XCFpiwZXg-AsHuWLQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097364854</pqid></control><display><type>article</type><title>Lithium nephropathy in Bipolar Disorder: a clinical challenge</title><source>Cambridge University Press:Jisc Collections:Cambridge University Press Read and Publish Agreement 2021-24 (Reading list)</source><source>PubMed Central</source><creator>Alario-Ruiz, C ; Arribas-Simon, B ; MartinezGimeno, P ; Calvo-Valcarcel, M ; Martin-Santiago, O</creator><creatorcontrib>Alario-Ruiz, C ; Arribas-Simon, B ; MartinezGimeno, P ; Calvo-Valcarcel, M ; Martin-Santiago, O</creatorcontrib><description>IntroductionLithium nephropathy can occur in long-term lithium-treated bipolar disorder patients. Key risk factors include duration of lithium exposure, cumulative dose, acute intoxication episodes, advanced age, and comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia, along with concurrent use of antipsychotics. The clinical presentation is gradual, with mild proteinuria, often accompanied by arginine vasopressin resistance. Histological studies show a correlation between interstitial fibrosis and cumulative lithium duration. Approximately 15 to 25 per cent of exposed patients may experience a gradual decline in glomerular filtration rate. The outcome after lithium discontinuation varies.ObjectivesThis case study aims to analyze and document the clinical presentation, diagnosis, and management of lithium nephropathy in a patient with Bipolar Disorder.MethodsWe gathered data on the medical history, lab results, and treatment approach for a patient with Bipolar Disorder.ResultsThe patient, a 50-year-old woman, had been under the care of Psychiatry since 2008 due to a diagnosis of Bipolar Disorder Type I. During this time, she had experienced depressive and manic episodes but had not presented significant symptom decompensation for the past 14 years, successfully managed with lithium at a current dose of 600 mg per day. However, on this occasion, the patient sought hospitalization due to recent behavioural disturbances, including restlessness, disinhibition, abrupt changes in behaviour, pressured speech, sleep problems, agitation, and aggression. The patient also reported an increased sense of polyuria and polydipsia. Evaluation in the emergency department revealed elevated lithium levels of 1.47 mmol/L and hypokalemia, that justified lithium withdrawal. After lithium levels decreased, an estimated glomerular filtration rate remained low. She was diagnosed with lithium nephropathy, an adverse effect of long-term lithium therapy. Treatment with lithium changed to sodium valproate. Treatment with asenapine started and sustained for two months. Over the following two years, the patient experienced four additional hospital admissions in Psychiatry due to manic episodes.ConclusionsLong-term lithium therapy can lead to lithium nephropathy with symptoms such as polyuria, polydipsia, and acute kidney failure. Consistent monitoring of patients receiving lithium is crucial to detect potential adverse effects.This case highlights the challenges in managing bipolar patients, as discontinuing lithium exacerbated symptoms despite switching to sodium valproate for nephropathy prevention. Long-term lithium treatment, while effective for bipolar disorder, poses significant renal risks. We emphasize continuous renal function monitoring and assessing the risk-benefit of lithium treatment while actively researching lithium nephropathy and its impact on glomerular function.Disclosure of InterestNone Declared</description><identifier>ISSN: 0924-9338</identifier><identifier>EISSN: 1778-3585</identifier><identifier>DOI: 10.1192/j.eurpsy.2024.890</identifier><language>eng</language><publisher>Paris: Cambridge University Press</publisher><subject>Bipolar disorder ; Lithium ; Patients ; Polyuria ; Psychotropic drugs</subject><ispartof>European psychiatry, 2024-08, Vol.67 (S1), p.S429-S430</ispartof><rights>The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association. This work is licensed under the Creative Commons Attribution License This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Alario-Ruiz, C</creatorcontrib><creatorcontrib>Arribas-Simon, B</creatorcontrib><creatorcontrib>MartinezGimeno, P</creatorcontrib><creatorcontrib>Calvo-Valcarcel, M</creatorcontrib><creatorcontrib>Martin-Santiago, O</creatorcontrib><title>Lithium nephropathy in Bipolar Disorder: a clinical challenge</title><title>European psychiatry</title><description>IntroductionLithium nephropathy can occur in long-term lithium-treated bipolar disorder patients. Key risk factors include duration of lithium exposure, cumulative dose, acute intoxication episodes, advanced age, and comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia, along with concurrent use of antipsychotics. The clinical presentation is gradual, with mild proteinuria, often accompanied by arginine vasopressin resistance. Histological studies show a correlation between interstitial fibrosis and cumulative lithium duration. Approximately 15 to 25 per cent of exposed patients may experience a gradual decline in glomerular filtration rate. The outcome after lithium discontinuation varies.ObjectivesThis case study aims to analyze and document the clinical presentation, diagnosis, and management of lithium nephropathy in a patient with Bipolar Disorder.MethodsWe gathered data on the medical history, lab results, and treatment approach for a patient with Bipolar Disorder.ResultsThe patient, a 50-year-old woman, had been under the care of Psychiatry since 2008 due to a diagnosis of Bipolar Disorder Type I. During this time, she had experienced depressive and manic episodes but had not presented significant symptom decompensation for the past 14 years, successfully managed with lithium at a current dose of 600 mg per day. However, on this occasion, the patient sought hospitalization due to recent behavioural disturbances, including restlessness, disinhibition, abrupt changes in behaviour, pressured speech, sleep problems, agitation, and aggression. The patient also reported an increased sense of polyuria and polydipsia. Evaluation in the emergency department revealed elevated lithium levels of 1.47 mmol/L and hypokalemia, that justified lithium withdrawal. After lithium levels decreased, an estimated glomerular filtration rate remained low. She was diagnosed with lithium nephropathy, an adverse effect of long-term lithium therapy. Treatment with lithium changed to sodium valproate. Treatment with asenapine started and sustained for two months. Over the following two years, the patient experienced four additional hospital admissions in Psychiatry due to manic episodes.ConclusionsLong-term lithium therapy can lead to lithium nephropathy with symptoms such as polyuria, polydipsia, and acute kidney failure. Consistent monitoring of patients receiving lithium is crucial to detect potential adverse effects.This case highlights the challenges in managing bipolar patients, as discontinuing lithium exacerbated symptoms despite switching to sodium valproate for nephropathy prevention. Long-term lithium treatment, while effective for bipolar disorder, poses significant renal risks. We emphasize continuous renal function monitoring and assessing the risk-benefit of lithium treatment while actively researching lithium nephropathy and its impact on glomerular function.Disclosure of InterestNone Declared</description><subject>Bipolar disorder</subject><subject>Lithium</subject><subject>Patients</subject><subject>Polyuria</subject><subject>Psychotropic drugs</subject><issn>0924-9338</issn><issn>1778-3585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNotzk9LwzAYBvAgCs7pB_BW8Nz5Jm_SJIIHnf8GAy96LmmSrildU9P2sG_vcJ4eeOD58RByS2FFqWb37crPaRgPKwaMr5SGM7KgUqochRLnZAGa8VwjqktyNY4tAJUAxYI8bsPUhHmf9X5oUhzM1Byy0GfPYYidSdlLGGNyPj1kJrNd6IM1XWYb03W-3_lrclGbbvQ3_7kk32-vX-uPfPv5vlk_bXNHUUKutBJQKGkrVQuUVCkQoqISUSPjRnPU4Kh2BThnFefCGcuBAa_scYYel2Rzcl00bTmksDfpUEYTyr8ipl1p0hRs50uPBQNdV7WjlBdgKpQoal87g-CR6aN1d7KGFH9mP05lG-fUH--XCFpiwZXg-AsHuWLQ</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Alario-Ruiz, C</creator><creator>Arribas-Simon, B</creator><creator>MartinezGimeno, P</creator><creator>Calvo-Valcarcel, M</creator><creator>Martin-Santiago, O</creator><general>Cambridge University Press</general><scope>DOA</scope></search><sort><creationdate>20240801</creationdate><title>Lithium nephropathy in Bipolar Disorder: a clinical challenge</title><author>Alario-Ruiz, C ; Arribas-Simon, B ; MartinezGimeno, P ; Calvo-Valcarcel, M ; Martin-Santiago, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d1370-89850687cb8f537188055b17339324a94390d19d60ddc8445dac40204bc0683e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bipolar disorder</topic><topic>Lithium</topic><topic>Patients</topic><topic>Polyuria</topic><topic>Psychotropic drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alario-Ruiz, C</creatorcontrib><creatorcontrib>Arribas-Simon, B</creatorcontrib><creatorcontrib>MartinezGimeno, P</creatorcontrib><creatorcontrib>Calvo-Valcarcel, M</creatorcontrib><creatorcontrib>Martin-Santiago, O</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>European psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alario-Ruiz, C</au><au>Arribas-Simon, B</au><au>MartinezGimeno, P</au><au>Calvo-Valcarcel, M</au><au>Martin-Santiago, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lithium nephropathy in Bipolar Disorder: a clinical challenge</atitle><jtitle>European psychiatry</jtitle><date>2024-08-01</date><risdate>2024</risdate><volume>67</volume><issue>S1</issue><spage>S429</spage><epage>S430</epage><pages>S429-S430</pages><issn>0924-9338</issn><eissn>1778-3585</eissn><abstract>IntroductionLithium nephropathy can occur in long-term lithium-treated bipolar disorder patients. Key risk factors include duration of lithium exposure, cumulative dose, acute intoxication episodes, advanced age, and comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia, along with concurrent use of antipsychotics. The clinical presentation is gradual, with mild proteinuria, often accompanied by arginine vasopressin resistance. Histological studies show a correlation between interstitial fibrosis and cumulative lithium duration. Approximately 15 to 25 per cent of exposed patients may experience a gradual decline in glomerular filtration rate. The outcome after lithium discontinuation varies.ObjectivesThis case study aims to analyze and document the clinical presentation, diagnosis, and management of lithium nephropathy in a patient with Bipolar Disorder.MethodsWe gathered data on the medical history, lab results, and treatment approach for a patient with Bipolar Disorder.ResultsThe patient, a 50-year-old woman, had been under the care of Psychiatry since 2008 due to a diagnosis of Bipolar Disorder Type I. During this time, she had experienced depressive and manic episodes but had not presented significant symptom decompensation for the past 14 years, successfully managed with lithium at a current dose of 600 mg per day. However, on this occasion, the patient sought hospitalization due to recent behavioural disturbances, including restlessness, disinhibition, abrupt changes in behaviour, pressured speech, sleep problems, agitation, and aggression. The patient also reported an increased sense of polyuria and polydipsia. Evaluation in the emergency department revealed elevated lithium levels of 1.47 mmol/L and hypokalemia, that justified lithium withdrawal. After lithium levels decreased, an estimated glomerular filtration rate remained low. She was diagnosed with lithium nephropathy, an adverse effect of long-term lithium therapy. Treatment with lithium changed to sodium valproate. Treatment with asenapine started and sustained for two months. Over the following two years, the patient experienced four additional hospital admissions in Psychiatry due to manic episodes.ConclusionsLong-term lithium therapy can lead to lithium nephropathy with symptoms such as polyuria, polydipsia, and acute kidney failure. Consistent monitoring of patients receiving lithium is crucial to detect potential adverse effects.This case highlights the challenges in managing bipolar patients, as discontinuing lithium exacerbated symptoms despite switching to sodium valproate for nephropathy prevention. Long-term lithium treatment, while effective for bipolar disorder, poses significant renal risks. We emphasize continuous renal function monitoring and assessing the risk-benefit of lithium treatment while actively researching lithium nephropathy and its impact on glomerular function.Disclosure of InterestNone Declared</abstract><cop>Paris</cop><pub>Cambridge University Press</pub><doi>10.1192/j.eurpsy.2024.890</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0924-9338 |
ispartof | European psychiatry, 2024-08, Vol.67 (S1), p.S429-S430 |
issn | 0924-9338 1778-3585 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_e36209fbfd11460ab3735fefda30e329 |
source | Cambridge University Press:Jisc Collections:Cambridge University Press Read and Publish Agreement 2021-24 (Reading list); PubMed Central |
subjects | Bipolar disorder Lithium Patients Polyuria Psychotropic drugs |
title | Lithium nephropathy in Bipolar Disorder: a clinical challenge |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A48%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lithium%20nephropathy%20in%20Bipolar%20Disorder:%20a%20clinical%20challenge&rft.jtitle=European%20psychiatry&rft.au=Alario-Ruiz,%20C&rft.date=2024-08-01&rft.volume=67&rft.issue=S1&rft.spage=S429&rft.epage=S430&rft.pages=S429-S430&rft.issn=0924-9338&rft.eissn=1778-3585&rft_id=info:doi/10.1192/j.eurpsy.2024.890&rft_dat=%3Cproquest_doaj_%3E3097364854%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d1370-89850687cb8f537188055b17339324a94390d19d60ddc8445dac40204bc0683e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3097364854&rft_id=info:pmid/&rfr_iscdi=true |